{"id":78523,"date":"2026-09-03T17:24:37","date_gmt":"2026-09-03T09:24:37","guid":{"rendered":"https:\/\/flcube.com\/?p=78523"},"modified":"2026-09-03T17:24:38","modified_gmt":"2026-09-03T09:24:38","slug":"biocytogen-signs-non-exclusive-nanobody-licensing-deal-with-qilu-pharmaceutical-for-innovative-neurological-drug-rd","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78523","title":{"rendered":"Biocytogen Signs Non\u2011Exclusive Nanobody Licensing Deal with Qilu Pharmaceutical for Innovative Neurological Drug R&D"},"content":{"rendered":"\n

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.<\/strong> (HKG: 2315<\/a>; SHA: 688796<\/a>) announced that it has signed a non\u2011exclusive licensing agreement with Qilu Pharmaceutical<\/strong> for a fully human nanobody<\/strong> molecule, supporting Qilu’s<\/strong> R&D exploration in innovative neurological drug projects. The collaboration, built on Biocytogen’s<\/strong> proprietary RenNano platform, delivers an upfront payment with milestone eligibility and extends the company’s discovery engine into one of pharma’s most challenging therapeutic frontiers \u2014 the central nervous system.<\/p>\n\n\n\n

Deal Terms at a Glance<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Parties<\/td>Biocytogen<\/strong> (HKG: 2315; SHA: 688796) and Qilu Pharmaceutical<\/strong><\/td><\/tr>
Structure<\/td>Non\u2011exclusive licensing agreement<\/td><\/tr>
Asset<\/td>Fully human nanobody<\/strong> molecule (RenNano platform\u2011derived)<\/td><\/tr>
Purpose<\/td>Support Qilu Pharmaceutical’s<\/strong> R&D in innovative neurological drug projects<\/td><\/tr>
Upfront Payment<\/td>Undisclosed amount, confirmed as part of the agreement<\/td><\/tr>
Milestones<\/td>Eligible development, regulatory, and commercial milestone payments<\/td><\/tr>
Other Financial Terms<\/td>Not disclosed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Platform & Asset Profile<\/h2>\n\n\n\n